1. Home
  2. ELUT vs BCTX Comparison

ELUT vs BCTX Comparison

Compare ELUT & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Elutia Inc.

ELUT

Elutia Inc.

HOLD

Current Price

$0.84

Market Cap

42.5M

Sector

Health Care

ML Signal

HOLD

BCTX

BriaCell Therapeutics Corp.

HOLD

Current Price

$3.41

Market Cap

36.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELUT
BCTX
Founded
2015
2014
Country
United States
Canada
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
42.5M
36.6M
IPO Year
2020
2025

Fundamental Metrics

Financial Performance
Metric
ELUT
BCTX
Price
$0.84
$3.41
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 100.2K
84.8K
Earning Date
11-05-2026
12-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 146.77
N/A
EPS
★ N/A
N/A
Revenue
★ $12,293,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$380.95
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.50
$2.60
52 Week High
$1.39
$13.90

Technical Indicators

Market Signals
Indicator
ELUT
BCTX
Relative Strength Index (RSI) 50.91 38.37
Support Level $0.74 $3.35
Resistance Level $0.87 $3.74
Average True Range (ATR) 0.06 0.21
MACD 0.01 -0.06
Stochastic Oscillator 65.53 9.08

Price Performance

Historical Comparison
ELUT
BCTX

About ELUT Elutia Inc.

Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.

About BCTX BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

Share on Social Networks: